Somatic Mutations Altering EZH2 (Tyr641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal-center Origin
Authors
Affiliations
Follicular lymphoma (FL) and the GCB subtype of diffuse large B-cell lymphoma (DLBCL) derive from germinal center B cells. Targeted resequencing studies have revealed mutations in various genes encoding proteins in the NF-kappaB pathway that contribute to the activated B-cell (ABC) DLBCL subtype, but thus far few GCB-specific mutations have been identified. Here we report recurrent somatic mutations affecting the polycomb-group oncogene EZH2, which encodes a histone methyltransferase responsible for trimethylating Lys27 of histone H3 (H3K27). After the recent discovery of mutations in KDM6A (UTX), which encodes the histone H3K27me3 demethylase UTX, in several cancer types, EZH2 is the second histone methyltransferase gene found to be mutated in cancer. These mutations, which result in the replacement of a single tyrosine in the SET domain of the EZH2 protein (Tyr641), occur in 21.7% of GCB DLBCLs and 7.2% of FLs and are absent from ABC DLBCLs. Our data are consistent with the notion that EZH2 proteins with mutant Tyr641 have reduced enzymatic activity in vitro.
Polycomb repressive complex 2 (PRC2) pathway's role in cancer cell plasticity and drug resistance.
Goleij P, Heidari M, Tabari M, Hadipour M, Rezaee A, Javan A Funct Integr Genomics. 2025; 25(1):53.
PMID: 40048009 DOI: 10.1007/s10142-025-01563-8.
Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancers.
Najia M, Jha D, Zhang C, Laurent B, Kubaczka C, Markel A bioRxiv. 2025; .
PMID: 39975048 PMC: 11838449. DOI: 10.1101/2025.01.31.635709.
YPEL2 regulates the efficacy of BRD4-EZH2 dual targeting in EZH2 germinal center-derived lymphoma.
Chamorro-Jorganes A, Profitos-Peleja N, Recasens-Zorzo C, Valero J, Reyes-Garau D, Magnano L Neoplasia. 2025; 61:101131.
PMID: 39914169 PMC: 11847303. DOI: 10.1016/j.neo.2025.101131.
Exploring oncogenic roles and clinical significance of EZH2: focus on non-canonical activities.
Wozniak M, Czyz M Ther Adv Med Oncol. 2025; 17():17588359241306026.
PMID: 39776536 PMC: 11705335. DOI: 10.1177/17588359241306026.
Targeting EZH2 in Cancer: Mechanisms, Pathways, and Therapeutic Potential.
Gilardini Montani M, Benedetti R, Cirone M Molecules. 2025; 29(24.
PMID: 39769907 PMC: 11678268. DOI: 10.3390/molecules29245817.